menu

Bispecific Discovery

High-Performance Bispecific Discovery Services

Invenra’s Bispecific Discovery Service offers a streamlined, end-to-end solution for generating high-quality therapeutic candidates by integrating the premier B-Body® platform with advanced high-throughput screening. This service utilizes a human IgG-like scaffold engineered with proprietary domain-substitution technology to ensure perfect chain pairing and industry-leading yields (6–11 g/L), effectively eliminating the developability and stability hurdles common in multispecific programs. By deploying a sophisticated 12×12 matrix screening workflow, Invenra rapidly identifies lead panels with the precise affinity and epitope diversity required for complex mechanisms of action, delivering clinical-ready molecules optimized for subcutaneous delivery and standard CMC processes.

Our new Rapid Bispecific Discovery Services powered by the B-Body® Bispecific Platform, deliver lead panels in just 2–4 months through functional screening of 250+ bispecific combinations from 90 parallel discovery screens.

Fast-track your therapeutic antibody development today—contact us to learn more!

Outlne of the Rapid Discovery Process

Outline of the Rapid Antibody Discovery Process Invenra’s Rapid Discovery Services provide an efficient, industry-leading approach to discovering monoclonal and bispecific antibodies. With cutting-edge phage display technology and our streamlined workflow, we deliver high-quality antibody leads in record time.

Rapid Bispecific Discovery

Features:

  • Inputs: Target ID(s), recombinant proteins, and cell lines
  • Deliverables: 10 unique B-Body® Bispecific Antibody sequences
  • Timeline – 4 months from DNA sequence submission to delivery

Process:

  1. Assessment – Invenra assesses target feasibility and compatibility for the Rapid Discovery Workflow
  2. Handoff – Clients supply purified recombinant antigens and necessary cell lines, or Invenra can source materials for an additional fee
  3. Library Screening – Invenra screens >30 proprietary human phage libraries under three selection conditions, conducting 90 screens in parallel
  4. Binding Validation – Cross-reactivity testing with up to three additional species/related proteins and affinity (KD) measurements
  5. Bispecific Expression – A 12×12 B-Body Bispecific matrix in two orientations (a total of 288 total combinations) is expressed, purified, and screened
  6. Selection and Assay – Top candidates are confirmed for target binding, self-association, polyreactivity, and functionality using a high-throughput screening assay
  7. Delivery – Data is shared with the client, and the top 10 B-Body Bispecific sequences are delivered

Advantages:

  • Speed – Fastest timelines in the industry for bispecific discovery
  • Proprietary Libraries – Gain access to Invenra’s proprietary antibody libraries, and the best possible lead molecules
  • Seamless B-Body integration – Build your bispecifics on the premiere bispecific platform with CMC-ready, in-platform discovery and proven performance
  • Flexible Commercial Licensing Options – Please contact us to discuss pricing and terms

Get Started with Invenra Bispecific Antibody Discovery

For more information on our current service offerings, please complete the form below: